Sugi Predict

Sugi Predict / Compounds / Mecloxamine

Mecloxamine

Mecloxamine

SCHEMBL249953

CC(CN(C)C)OC(C)(c1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 1/20 0.43
▸ CYP2D6 P10635 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ SLC6A4 P31645 5/20 0.42
▸ KCNH2 Q12809 5/20 0.42
▸ CHRM2 P08172 5/20 0.42
▸ CHRM1 P11229 4/20 0.42
▸ SLC6A2 P23975 4/20 0.42
▸ SLC6A3 Q01959 4/20 0.42
▸ HRH3 Q9Y5N1 4/20 0.42
▸ HTR1A P08908 3/20 0.42
▸ ADRA2A P08913 3/20 0.42
▸ ADRA1A P35348 3/20 0.42
▸ DRD1 P21728 2/20 0.42
▸ OPRM1 P35372 2/20 0.42
▸ DRD3 P35462 2/20 0.42
▸ TBXA2R P21731 1/20 0.42
▸ ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mecloxamine SCHEMBL5705589 0.86 MAPT (0.41) BCL2CYP2D6ALDH1A1CYP2C19HSD17B10
Chlorphenoxamine SCHEMBL29208 0.73 CHRM2 (0.61) BCL2CYP2D6ALDH1A1CYP2C19SLC6A4
Chlorphenoxamine SCHEMBL125112 0.72 CHRM2 (0.59) BCL2CYP2D6ALDH1A1CYP2C19SLC6A4
Chlorphenoxamine SCHEMBL1649036 0.71 CHRM2 (0.62) BCL2CYP2D6ALDH1A1CYP2C19SLC6A4
SCHEMBL13772372 0.70 CHRM2 (0.49) BCL2CYP2D6ALDH1A1CYP2C19SLC6A4
SCHEMBL13641887 0.67 MAPK1 (0.46) CYP2D6ALDH1A1CYP2C19HSD17B10MAPT
Chlorphenoxamine SCHEMBL13723924 0.67 CHRM2 (0.61) BCL2CYP2D6ALDH1A1CYP2C19HSD17B10
SCHEMBL10733508 0.67 CHRM2 (0.61) BCL2CYP2D6ALDH1A1CYP2C19SLC6A4
SCHEMBL18473516 0.67 CTSK (0.39) ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL3088064 0.67 ALDH1A1 (0.48) CYP2D6ALDH1A1CYP2C19HSD17B10KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116348492-A Tetrahedral antibodies 生物分子控股有限责任公司 2023-06-27 — — CN claimed
CN-115844822-A Oral drug-loaded micelle composition and preparation method thereof 上海交通大学医学院附属第九人民医院 2023-03-28 — — CN claimed
CN-211021996-U Bed sheet with good warm-keeping and anti-mite performances 江苏颂琪纺织品有限公司 2020-07-17 — — CN claimed
US-9770514-B2 Tamper-resistant pharmaceutical dosage forms ExxPharma Therapeutics LLC (US) 2017-09-26 — — US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20150064250-A1 Tamper-Resistant Pharmaceutical Dosage Forms ExxPharma Therapeutics LLC (US) 2015-03-05 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
EP-1273301-B1 Pharmaceutical preparations based on active ingredients susceptible to illicit administration ALTERGON SA (CH) 2006-09-06 — — EP claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 — — CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed
US-20260097102-A1 Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors REGENERON PHARMA (US) 2026-04-09 — — US disclosed
US-12472241-B2 Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors REGENERON PHARMACEUTICALS, INC. (US) 2025-11-18 — — US disclosed
WO-1996040084-A1 COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT NOVEN PHARMACEUTICALS, INC. (US) 1996-12-19 — — WO disclosed
US-5446070-A Flexible, finite, bioadhesive, therapeutical agent in solid form NOVER PHARMACEUTICALS, INC. (US) 1995-08-29 — — US disclosed
US-4399002-A Large organic cation-selective electrodes UNIVERSITY PATENTS, INC. (US) 1983-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097102-A1 Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors ALOX15, ALOX15B, ALOX5 BCL2 4458/4885CYP2D6 217/4885ALDH1A1 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.